Circulating microRNAs as biomarkers for diabetic neuropathy: A novel approach

Xourgia, Eleni; Papazafiropoulou, Athanasia; Μelidonis, Αndreas

doi:10.5493/wjem.v8.i3.18

Cited by 22 publications

(16 citation statements)

References 25 publications

(30 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 5 The key involvement of microRNAs (miRNAs or miRs) in diabetes and its complications, which is by regulating multiple biological pathways, has been highlighted in several studies. 6 , 7 , 8 …”

Section: Introductionmentioning

confidence: 99%

RETRACTED: miR-363 Alleviates Detrusor Fibrosis via the TGF-Î²1/Smad Signaling Pathway by Targeting Col1a2 in Rat Models of STZ-Induced T2DM

Zhang

2020

Molecular Therapy - Nucleic Acids

View full text Add to dashboard Cite

Dysregulated expression of microRNAs (miRNAs or miRs) has been implicated in the pathophysiology of type 2 diabetes mellitus (T2DM). However, their underlying role in the complication of detrusor fibrosis remains poorly understood. Therefore, this study aimed to examine the potential functional relevance of miR-363 in detrusor fibrosis of rats with streptozotocin (STZ)-induced T2DM through the predicted target gene collagen type I alpha 2 (Col1a2). Immunohistochemical analysis found an increase in the positive expression of collagen type III alpha 1 (Col3a1) and Col1a2 in detrusor tissues, where miR-363 expression was decreased. Next, gain- and loss-of-function experiments were performed to clarify the effects of miR-363 and Col1a2 on the activities of bladder detrusor cells. Of note, binding affinity between miR-363 and Col1a2 was verified by a dual-luciferase reporter gene assay and RNA immunoprecipitation (RIP) assay. Upregulated miR-363 inhibited Col1a2 expression, which led to increased expression of B-cell lymphoma 2 (Bcl-2) and Smad7 and accelerated cell viability, along with decreases in cell apoptosis and Col3a1, Bcl-2-associated X protein (Bax), transforming growth factor (TGF)-β1, and Smad4 expressions. In conclusion, miR-363 upregulation reduces detrusor fibrosis in rats with STZ-induced T2DM through suppression of the TGF-β1/Smad signaling pathway by targeting Col1a2. Therefore, our study provided further insights for the development of new therapeutic targets for T2DM.

show abstract

Section: Introductionmentioning

confidence: 99%

RETRACTED: miR-363 Alleviates Detrusor Fibrosis via the TGF-Î²1/Smad Signaling Pathway by Targeting Col1a2 in Rat Models of STZ-Induced T2DM

Zhang

2020

Molecular Therapy - Nucleic Acids

View full text Add to dashboard Cite

show abstract

“…In the context of diabetes, hyperglycemia, hypoxia, and inflammation affect miRNA biogenesis and release. Consequently, these alterations in the miRNA profile are associated with multiple microvascular complications (20)(21)(22)(23). Of note, a significant portion of miRNAs was found to be specifically packaged into extracellular vesicles that express cell-type-specific proteins to mediate their different functions (24).…”

Section: Function Of Micrornasmentioning

confidence: 99%

“…They found that miR-17-1-3p, miR-330-5p, and miR-346 are potent promoters of DN (113). Xourgia et al proposed that miR-146, miR-499a, and miR-199a-3p are possible biomarkers of DN (21). In addition, miR-181a-1, miR-541, miR-341, and miR-203 were reported to be dysregulated in an animal model of DN (116).…”

Section: Mirnas As Biomarkers In the Diagnosis Of Diabetic Neuropathymentioning

confidence: 99%

Emerging Roles of microRNAs as Biomarkers and Therapeutic Targets for Diabetic Neuropathy

et al. 2020

View full text Add to dashboard Cite

Diabetic neuropathy (DN) is the most prevalent chronic complication of diabetes mellitus. The exact pathophysiological mechanisms of DN are unclear; however, communication network dysfunction among axons, Schwann cells, and the microvascular endothelium likely play an important role in the development of DN. Mounting evidence suggests that microRNAs (miRNAs) act as messengers that facilitate intercellular communication and may contribute to the pathogenesis of DN. Deregulation of miRNAs is among the initial molecular alterations observed in diabetics. As such, miRNAs hold promise as biomarkers and therapeutic targets. In preclinical studies, miRNA-based treatment of DN has shown evidence of therapeutic potential. But this therapy has been hampered by miRNA instability, targeting specificity, and potential toxicities. Recent findings reveal that when packaged within extracellular vesicles, miRNAs are resistant to degradation, and their delivery efficiency and therapeutic potential is markedly enhanced. Here, we review the latest research progress on the roles of miRNAs as biomarkers and as potential clinical therapeutic targets in DN. We also discuss the promise of exosomal miRNAs as therapeutics and provide recommendations for future research on miRNA-based medicine.

show abstract

“…In addition, distinct circulating miRNA profiles between subjects with obesity and T2D aroused considerable attention given their potential as biomarkers for these diseases. Indeed, strong correlations were found between some circulating miRNAs and the development of metabolic syndrome [ 59 ], obesity [ 60 , 61 ], diabetes [ 32 , 62 , 63 ] and/or linked to CVD [ 37 , 64 ]. Nowadays, miRNAs are attractive candidates as innovative biomarkers and have been proposed to promote the progression to diabetes [ 29 , 33 , 62 ].…”

Section: Mirnas and Cardiovascular Risk Factors (Crfs)mentioning

confidence: 99%

Does microRNA Perturbation Control the Mechanisms Linking Obesity and Diabetes? Implications for Cardiovascular Risk

Sala

Crestani

Garavelli

et al. 2020

IJMS

View full text Add to dashboard Cite

Metabolic disorders such as obesity and type 2 diabetes (T2D) are considered the major risk factors for the development of cardiovascular diseases (CVD). Although the pathological mechanisms underlying the mutual development of obesity and T2D are difficult to define, a better understanding of the molecular aspects is of utmost importance to identify novel therapeutic targets. Recently, a class of non-coding RNAs, called microRNAs (miRNAs), are emerging as key modulators of metabolic abnormalities. There is increasing evidence supporting the role of intra- and extracellular miRNAs as determinants of the crosstalk between adipose tissues, liver, skeletal muscle and other organs, triggering the paracrine communication among different tissues. miRNAs may be considered as risk factors for CVD due to their correlation with cardiovascular events, and in particular, may be related to the most prominent risk factors. In this review, we describe the associations observed between miRNAs expression levels and the most common cardiovascular risk factors. Furthermore, we sought to depict the molecular aspect of the interplay between obesity and diabetes, investigating the role of microRNAs in the interorgan crosstalk. Finally, we discussed the fascinating hypothesis of the loss of protective factors, such as antioxidant defense systems regulated by such miRNAs.

show abstract

Circulating microRNAs as biomarkers for diabetic neuropathy: A novel approach

Cited by 22 publications

References 25 publications

RETRACTED: miR-363 Alleviates Detrusor Fibrosis via the TGF-Î²1/Smad Signaling Pathway by Targeting Col1a2 in Rat Models of STZ-Induced T2DM

RETRACTED: miR-363 Alleviates Detrusor Fibrosis via the TGF-Î²1/Smad Signaling Pathway by Targeting Col1a2 in Rat Models of STZ-Induced T2DM

Emerging Roles of microRNAs as Biomarkers and Therapeutic Targets for Diabetic Neuropathy

Does microRNA Perturbation Control the Mechanisms Linking Obesity and Diabetes? Implications for Cardiovascular Risk

Contact Info

Product

Resources

About